Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. The company has 8 approved antibodies used in 8 marketed products, covering cancer indications and autoimmune diseases. Proprietary, marketed with partners: Epkinly/Tepkinly for the treatment of Relapsed/refractory diffuse large B-cell lymphoma Tivdak for the treatment of previously treated recurrent or metastatic cervical cancer Marketed by partners: Darzalex (IV) / Darzalex Faspro for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain amyloidosis Kesimpta for the treatment of relapsing remitting multiple sclerosis Rybrevant for the treatment of non-small-cell lung cancer Wikipedia